Previous close | 142.40 |
Open | 141.45 |
Bid | 139.80 x 40000 |
Ask | 141.15 x 40000 |
Day's range | 139.75 - 141.60 |
52-week range | 112.45 - 158.15 |
Volume | |
Avg. volume | 582 |
Market cap | 216.653B |
Beta (5Y monthly) | 0.17 |
PE ratio (TTM) | 37.17 |
EPS (TTM) | 3.76 |
Earnings date | 12 Nov 2024 |
Forward dividend & yield | 2.73 (1.92%) |
Ex-dividend date | 08 Aug 2024 |
1y target est | N/A |
Astrazeneca (AZN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
AZN inks an agreement with CSPC Pharmaceutical to develop a novel lipid-lowering therapy targeting various cardiovascular diseases.
Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.